Caribou Biosciences Q4 EPS $(0.39) Misses $(0.37) Estimate, Sales $3.56M Miss $4.61M Estimate
Portfolio Pulse from Happy Mohamed
Caribou Biosciences (NASDAQ:CRBU) reported Q4 earnings with a loss of $(0.39) per share, missing the $(0.37) estimate, and sales of $3.56M, missing the $4.61M estimate. This represents an 11.36% increase in losses per share but a 3.63% decrease in sales compared to the same period last year.
March 11, 2024 | 8:22 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Caribou Biosciences reported a larger than expected loss per share and a miss on sales estimates for Q4, indicating a potential negative short-term impact on its stock price.
Missing both EPS and sales estimates typically leads to negative investor sentiment in the short term. The reported increase in losses per share and decrease in sales compared to the same period last year further contribute to potential downward pressure on CRBU's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100